Drug Trial News

RSS

Is cannabidiol effective against COVID-19?

A new study discusses the utility of CBD in treating the inflammatory symptoms of COVID-19

31 Jul 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

Oncology trial data not available for independent scrutiny, study finds

Despite a commitment from the pharmaceutical industry in 2014 to improve data transparency, more than half of the clinical trials that led to the United States Food and Drug Administration approving anticancer medicines over the past 10 years are not available for independent scrutiny, a multi-national study led by Flinders University has found.

28 Jul 2022

FDA clears IND application for MD Anderson-sponsored Phase I clinical study of OBX-115 therapy

The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for an MD Anderson-sponsored Phase I clinical study of OBX-115, Obsidian's lead engineered tumor infiltrating lymphocyte (TIL) therapy candidate.

21 Jul 2022

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

AbbVie today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

From AbbVie 21 Jul 2022

Nanotherapeutic compound may help treat inflammation, brain injury in patients with severe COVID-19

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chances of death, according to a new study from UTHealth Houston and other institutions.

20 Jul 2022

The potential of circular RNA COVID-19 vaccines

A new MedComm study describes the potential use of circular ribonucleic acid COVID-19 vaccines.

17 Jul 2022

Lumasiran shows efficacy and acceptable safety in patients with PH1 and advanced kidney disease

In patients with PH1 and advanced kidney disease, including patients on hemodialysis, use of Lumasiran shows substantial reductions in plasma oxalate levels with acceptable safety.

14 Jul 2022

Phase I clinical trial of new blocking antibody therapy shows promising results for the treatment of advanced medulloblastoma

Effective and safe treatments are needed for medulloblastoma - the most common type of cancerous brain tumor in children - especially for patients whose cancer has spread to the spinal cord.

14 Jul 2022

University of Oxford begins recruiting for Phase I trial of new TB vaccine

The University of Oxford has begun recruiting for a Phase I trial with a tuberculosis vaccine in human volunteers at Oxford to develop a new way to test the efficacy of future TB vaccines - with the first volunteers being challenged today (Wednesday).

12 Jul 2022

NIH launches clinical trial evaluating an experimental vaccine to prevent Nipah virus infection

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an investigational vaccine to prevent infection with Nipah virus.

11 Jul 2022

Monoclonal antibody treatment taken by hospitalized COVID-19 patients reduces mortality

A monoclonal antibody treatment taken by patients hospitalized with COVID-19 did not improve recovery time but did reduce deaths, according to a study published July 8 in The Lancet Respiratory Medicine.

8 Jul 2022

Clinical trial examining the combination of atezolizumab and chemoradiation for patients with limited-stage SCLC reaches accrual

The NRG Oncology/Alliance clinical trial NRG-LU005, examining the addition of the immunotherapy drug atezolizumab combined with chemoradiation for patients with limited-stage small cell lung cancer (SCLC) recently reached the trial's accrual goal of 506 patients.

8 Jul 2022

Low doses of a less commonly used drug may be a better treatment option for gout

Gout occurs when urate crystals accumulate in the joints, and xanthine oxidase inhibitors such as febuxostat are a mainstay of therapy to help reduce blood urate levels in affected patients.

7 Jul 2022

Trial: Convalescent plasma does not improve survival or recovery in hospitalized COVID-19 patients

Convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover, according to a national clinical trial led by Vanderbilt University Medical Center and published in the journal CHEST.

5 Jul 2022

Bladder cancer patients with ctDNA positivity respond very well to treatment with atezolizumab

Researchers who treated a group of post-surgery bladder cancer patients with the immunotherapy drug atezolizumab have found that patients whose blood contained circulating tumour DNA (ctDNA), responded very well to the treatment.

3 Jul 2022

UC enrolling patients for clinical trial of novel PTSD treatments

About 8% of Americans will experience post-traumatic stress disorder at some point in their lives, but there are still few effective options to treat the condition.

28 Jun 2022

Phase 1 clinical trial of new influenza vaccine begins at NIH Clinical Center in Bethesda

A Phase 1 clinical trial of a novel influenza vaccine has begun inoculating healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland.

28 Jun 2022

Varenicline improves quit rates among African American daily smokers

African Americans have been underrepresented in tobacco treatment research, including the clinical trials that led to the 2006 FDA approval of varenicline, the leading pharmacological treatment for smoking cessation commonly known by the brand name Chantix.

14 Jun 2022

Fezolinetant reduces the frequency and severity of menopausal hot flashes, study finds

Fezolinetant significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, associated with menopause, according to a Phase 3 industry-sponsored study being presented Saturday at ENDO 2022, the Endocrine Society's annual meeting in Atlanta, Ga.

13 Jun 2022

Previous
1
...
44
45
46
47
48
49
50
...
1156
Next